|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:tenofovir
|
|
gptkbp:activities
|
nucleotide reverse transcriptase inhibitor
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Viread
|
|
gptkbp:class
|
nucleotide analogs
antiretroviral agents
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
renal impairment
hypersensitivity to tenofovir
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:formulation
|
oral tablet
oral powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Viread
|
|
gptkbp:ingredients
|
gptkb:tenofovir_disoproxil_fumarate
C19 H30 N5 O10 P
|
|
gptkbp:interacts_with
|
other antiretrovirals
nephrotoxic drugs
|
|
gptkbp:invention
|
gptkb:2017
|
|
gptkbp:is_atype_of
|
J05 A F09
|
|
gptkbp:is_used_for
|
treatment of HIV
treatment of hepatitis B
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:packaging
|
gptkb:beer
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:products
|
gptkb:Atripla
gptkb:Truvada
gptkb:Biktarvy
gptkb:Descovy
|
|
gptkbp:research
|
HIV prevention
Pr EP
HIV treatment regimens
|
|
gptkbp:side_effect
|
gptkb:lipodystrophy
fatigue
headache
nausea
diarrhea
lactic acidosis
bone density loss
liver problems
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:weight
|
357.24 g/mol
|